deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04237116

A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) (pINPOINt)

A Randomized, Double-blind, Multicenter, 24-week Study of Subcutaneous Secukinumab to Assess Anti-interleukin-17A Treatment in Plaque Psoriasis Patients With Coexisting Non-alcoholic Fatty Liver Disease (pINPOINt)

Sponsor: Novartis Pharmaceuticals

Conditions Non-alcoholic Fatty Liver Disease Plaque Psoriasis
Interventions Control Arm - placebo Investigational Arm - secukinumab
Updated 16 times since 2020 Last updated: Feb 27, 2024 Started: Feb 19, 2020 Primary completion: Jun 29, 2021 Completion: Jul 23, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Non-alcoholic Fatty Liver Disease trials with similar outcome

Browse all Non-alcoholic Fatty Liver Disease trials

This PHASE3 trial investigates Non-alcoholic Fatty Liver Disease and Plaque Psoriasis and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 16 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2024 · 25 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Completed → Terminated

  5. Feb 2022 — Mar 2024 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Dec 2021 — Feb 2022 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  2. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  3. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  4. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  5. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  7. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  9. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

    Status: Suspended → Recruiting

  10. May 2020 — Aug 2020 [monthly]

    Suspended PHASE3

    Status: Not Yet Recruiting → Suspended

  11. Feb 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations